Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer

Arechavaleta-Velásco, Fabián; Cuevas-Antonio, Rocio; Dominguez-Lopez, Pablo; Estrada-Moscoso, Isaías; Imani-Razavi, Fazlollah Shahram; Zeferino-Toquero, Moises; Dı́az-Cueto, Laura

doi:10.1007/s12032-014-0132-3

Cited by 17 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, SNP rs11225395 was associated with an increased risk of developing melanoma [96] and ovarian cancer. Moreover, in ovarian cancer, a tendency towards worse overall survival was found [107]. In the case of HNSCC, no correlation between SNP rs11225395 and survival of the patients was found [78], nor was this SNP associated with risk of oral cancer [100].…”

Section: Resultsmentioning

confidence: 99%

“…Additionally, it should be noted that serum and plasma may give contradicting results; plasma contains blood cells including neutrophils, which might release additional MMP8 in the sample after collection. SNPs, which modulate MMP8 transcription and activity, seem to play the strongest role in cancer prognosis and are beneficial for breast [95,98], bladder [91,93] and gastric [36] cancer patients but detrimental in ovarian [107] cancer patients. Other SNPs and genetic modifications have been poorly studied or do not correlate with clinicopathological parameters.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of MMP8 in Cancer: A Systematic Review

Juurikka

Butler

Salo

et al. 2019

IJMS

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) have traditionally been considered as tumor promoting enzymes as they degrade extracellular matrix components, thus increasing the invasion of cancer cells. It has become evident, however, that MMPs can also cleave and alter the function of various non-matrix bioactive molecules, leading to both tumor promoting and suppressive effects. We applied systematic review guidelines to study MMP8 in cancer including the use of MMP8 as a prognostic factor or as a target/anti-target in cancer treatment, and its molecular mechanisms. A total of 171 articles met the inclusion criteria. The collective evidence reveals that in breast, skin and oral tongue cancer, MMP8 inhibits cancer cell invasion and proliferation, and protects patients from metastasis via cleavage of non-structural substrates. Conversely, in liver and gastric cancers, high levels of MMP8 worsen the prognosis. Expression and genetic alterations of MMP8 can be used as a prognostic factor by examination of the tumor and serum/plasma. We conclude, that MMP8 has differing effects on cancers depending on their tissue of origin. The use of MMP8 as a prognostic factor alone, or with other factors, seems to have potential. The molecular mechanisms of MMP8 in cancer further emphasize its role as an important regulator of bioactive molecules.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Role of MMP8 in Cancer: A Systematic Review

Juurikka

Butler

Salo

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Among these studies, 8 studies with 2 polymorphisms [ 11 , 12 , 14 , 15 , 18 , 19 ] (5 studies for MMP1 rs1799750, 3 studies for MMP3 rs34093618) involving 1019 ovarian cancer cases and 1609 controls could be quantitatively synthesized for meta-analysis. The remaining 12 studies with 12 polymorphisms [ 18 , 20 , 22 , 23 , 24 ] (12 polymorphisms including MMP2 C-1306T, MMP2 C-735T, MMP7 A-181G, MMP8 rs2155052, MMP8 rs11225395, MMP9 C-1562T, MMP9 rs6094237, MMP12 rs2276109, MMP13 rs17860523, MMP20 rs2292730, MMP20 rs12278250, MMP20 rs9787933) involving 2793 ovarian cancer cases and 3037 controls could not be quantitatively synthesized, thus the systematic review was performed. The flow diagram of study selection process was presented in Fig 1 .…”

Section: Resultsmentioning

confidence: 99%

Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review

Zhu

Sun

2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundPublished data on the relationship between matrix metalloproteinases (MMPs) polymorphisms and ovarian cancer risk have implicated inconclusive results. To evaluate the role of MMPs polymorphisms in ovarian cancer risk, a meta-analysis and systematic review were performed.MethodsMMPs polymorphisms which could be quantitatively synthesized were involved in meta-analysis. Five comparison models (homozygote model, heterozygote model, dominant model, recessive model, additive model) were carried out, a subgroup analysis was performed to clarify heterogeneity source. The remaining polymorphisms which could not be quantitatively synthesized were involved in systematic review.Results10 articles with 20 studies were included in this paper. Among those studies, 8 studies involving MMP1 rs1799750 and MMP3 rs34093618 could be meta-analyzed and 12 studies involving 12 polymorphisms could not. Meta-analysis showed that no associations were found between MMP1 rs1799750 (homozygote model: OR = 0.93, 95%CI = 0.70–1.23, POR = 0.60; heterozygote model: OR = 1.09, 95%CI = 0.78–1.54, POR = 0.61; dominant model: OR = 1.02, 95%CI = 0.83–1.25, POR = 0.84; recessive model: OR = 0.95, 95%CI = 0.75–1.21, POR = 0.67; additive model: OR = 1.00, 95%CI = 0.85–1.17, POR = 0.99), MMP3 rs34093618 (homozygote model: OR = 1.25, 95%CI = 0.70–2.24, POR = 0.46; heterozygote model: OR = 1.08, 95%CI = 0.51–2.31, POR = 0.84; dominant model: OR = 0.97, 95%CI = 0.68–1.38, POR = 0.85; recessive model: OR = 1.12, 95%CI = 0.69–1.80, POR = 0.65; additive model: OR = 1.01, 95%CI = 0.79–1.31, POR = 0.91) and ovarian cancer. Furthermore, similar results were detected in subgroup analysis. The systematic review on 12 polymorphisms suggested that MMP2 C-735T, MMP7 A-181G, MMP8 rs11225395, MMP9 rs6094237, MMP12 rs2276109, MMP20 rs2292730, MMP20 rs12278250, MMP20 rs9787933 might have a potential effect on ovarian cancer risk.ConclusionsIn summary, polymorphisms of MMPs might not be associated with ovarian cancer risk. However, it is necessary to conduct more larger-scale, multicenter, and high-quality studies in the future.

show abstract

“…For example, Kanamori and colleagues (Kanamori et al 1999) reported a guanine (G) insertion/deletion polymorphism within the promoter region of MMP1 possesses greater transcriptional activity, that the proportion of patients who contained the polymorphism was elevated in patients with ovarian cancer, and MMP1 expression was elevated in ovarian cancer tissue. Subsequent investigation into the association of promoter polymorphisms and cancer risk has questioned the role of promoter mutations in the expression of MMP1 (Wenham et al 2003, Li et al 2006) but has indicated a possible association between polymorphisms in the MMP7, MMP8, MMP12, or MMP13 promoters and the susceptibility to epithelium ovarian cancer in various populations (Li et al 2006, Li et al 2009, Arechavaleta-Velasco et al 2014). …”

Section: Mmps and Ovarian Cancermentioning

confidence: 99%

Ovarian cancer: involvement of the matrix metalloproteinases

Al-Alem

Curry

2015

Reproduction

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of death from gynecologic malignancies. Reasons for the high mortality rate associated with ovarian cancer include a late diagnosis at which time the cancer has metastasized throughout the peritoneal cavity. Cancer metastasis is facilitated by the remodeling of the extracellular tumor matrix by a family of proteolytic enzymes known as the matrix metalloproteinases (MMPs). There are 23 members in the MMP family, many of which have been reported to be associated with ovarian cancer. In the current paradigm, ovarian tumor cells and the surrounding stromal cells stimulate the synthesis and/or activation of various MMPs to aid in tumor growth, invasion, and eventual metastasis. This review sheds light on the different MMPs in the various types of ovarian cancer and their impact on the progression of this gynecologic malignancy.

show abstract

Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer

Cited by 17 publications

References 22 publications

The Role of MMP8 in Cancer: A Systematic Review

The Role of MMP8 in Cancer: A Systematic Review

Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review

Ovarian cancer: involvement of the matrix metalloproteinases

Contact Info

Product

Resources

About